5 research outputs found
Proteomic Analysis of the E3 Ubiquitin-Ligase Hakai Highlights a Role in Plasticity of the Cytoskeleton Dynamics and in the Proteasome System
Carcinoma, the most
common type of cancer, arises from epithelial
cells. The transition from adenoma to carcinoma is associated with
the loss of E-cadherin and, in consequence, the disruption of cell–cell
contacts. E-cadherin is a tumor suppressor, and it is down-regulated
during epithelial-to-mesenchymal transition (EMT); indeed, its loss
is a predictor of poor prognosis. Hakai is an E3 ubiquitin-ligase
protein that mediates E-cadherin ubiquitination, endocytosis and finally
degradation, leading the alterations of cell–cell contacts.
Although E-cadherin is the most established substrate for Hakai activity,
other regulated molecular targets for Hakai may be involved in cancer
cell plasticity during tumor progression. In this work we employed
an iTRAQ approach to explore novel molecular pathways involved in
Hakai-driven EMT during tumor progression. Our results show that Hakai
may have an important influence on cytoskeleton-related proteins,
extracellular exosome-associated proteins, RNA-related proteins and
proteins involved in metabolism. Moreover, a profound decreased expression
in several proteasome subunits during Hakai-driven EMT was highlighted.
Since proteasome inhibitors are becoming increasingly used in cancer
treatment, our findings suggest that the E3 ubiquitin-ligase, such
as Hakai, may be a better target than proteasome for using novel specific
inhibitors in tumor subtypes that follow EMT
Description of the TNM, histological subtype and grade of the evaluable patients, including TN patients.
<p>Only pathological T and N were considered.</p
Individual and familial features distribution in the global sample.
<p>Individual and familial features distribution in the global sample.</p
Description of the TNM, histological subtype and grade of the evaluable patients, excluding those TN patients.
<p>Only pathological T and N were considered.</p